Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 9/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.39 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20371098 | 0.87 | KMT2A (0.40) | KIF11KMT2AMEN1KCNH2SLC6A1 | |
| SCHEMBL24937040 | 0.83 | LMNA (0.46) | KIF11KMT2AMEN1KCNH2SLC6A1 | |
| SCHEMBL10434091 | 0.83 | LMNA (0.46) | KIF11KMT2AMEN1KCNH2SLC6A1 | |
| SCHEMBL10434128 | 0.83 | LMNA (0.46) | KIF11KMT2AMEN1KCNH2SLC6A1 | |
| SCHEMBL17423858 | 0.81 | KIF11 (0.50) | KIF11KMT2AMEN1KCNH2SLC6A1 | |
| SCHEMBL26230954 | 0.81 | KIF11 (0.50) | KIF11KMT2AMEN1KCNH2SLC6A1 | |
| SCHEMBL20371097 | 0.81 | KIF11 (0.50) | KIF11KMT2AMEN1KCNH2SLC6A1 | |
| SCHEMBL13388489 | 0.79 | KIF11 (0.50) | KIF11KCNH2SLC6A1SLC6A11 | |
| SCHEMBL30056424 | 0.79 | KIF11 (0.48) | KIF11KMT2AMEN1SLC6A1SLC6A11 | |
| SCHEMBL27240989 | 0.79 | SLC6A9 (0.41) | KIF11KMT2AMEN1SLC6A1SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193471-A1 | ß2GPI GENE EXPRESSION-SUPPRESSING NUCLEIC ACID CONJUGATE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193471-A1 | ß2GPI GENE EXPRESSION-SUPPRESSING NUCLEIC ACID CONJUGATE | GALNT2, ST6GAL1, SLC17A5 | KIF11 2975/4885KMT2A 2553/4885MEN1 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.